Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Comparative performance a… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Comparative performance and external validation of the multivariable PREDICTProstatetool for non-metastatic prostate cancer: a study in 69,206 men from Prostate Cancer data Base Sweden (PCBaSe)

Artikel i vetenskaplig tidskrift
Författare D. Thurtle
Ola Bratt
P. Stattin
P. Pharoah
V. Gnanapragasam
Publicerad i Bmc Medicine
Volym 18
Nummer/häfte 1
ISSN 1741-7015
Publiceringsår 2020
Publicerad vid Institutionen för kliniska vetenskaper, Avdelningen för urologi
Språk en
Länkar dx.doi.org/10.1186/s12916-020-01606...
Ämnesord Prostate cancer, Prognosis, Prostate cancer-specific mortality, PCSM, Survival, Overall mortality, Competing risks, Decision aid, risk-assessment, register, score, mortality, General & Internal Medicine
Ämneskategorier Urologi och njurmedicin

Sammanfattning

Background PREDICTProstateis an endorsed prognostic model that provides individualised long-term prostate cancer-specific and overall survival estimates. The model, derived from UK data, estimates potential treatment benefit on overall survival. In this study, we externally validated the model in a large independent dataset and compared performance to existing models and within treatment groups. Methods Men with non-metastatic prostate cancer and prostate-specific antigen (PSA) < 100 ng/ml diagnosed between 2000 and 2010 in the nationwide population-based Prostate Cancer data Base Sweden (PCBaSe) were included. Data on age, PSA, clinical stage, grade group, biopsy involvement, primary treatment and comorbidity were retrieved. Sixty-nine thousand two hundred six men were included with 13.9 years of median follow-up. Fifteen-year survival estimates were calculated using PREDICTProstatefor prostate cancer-specific mortality (PCSM) and all-cause mortality (ACM). Discrimination was assessed using Harrell's concordance (c)-index in R. Calibration was evaluated using cumulative available follow-up in Stata (TX, USA). Results Overall discrimination of PREDICTProstatewas good with c-indices of 0.85 (95% CI 0.85-0.86) for PCSM and 0.79 (95% CI 0.79-0.80) for ACM. Overall calibration of the model was excellent with 25,925 deaths predicted and 25,849 deaths observed. Within the conservative management and radical treatment groups, c-indices for 15-year PCSM were 0.81 and 0.78, respectively. Calibration also remained good within treatment groups. The discrimination of PREDICT Prostate significantly outperformed the EAU, NCCN and CAPRA scores for both PCSM and ACM within this cohort overall. A key limitation is the use of retrospective cohort data. Conclusions This large external validation demonstrates that PREDICTProstateis a robust and generalisable model to aid clinical decision-making.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?